Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms

Chandra Engel, 2019, Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml, Scand J Urol, 69, 1 Verhamme, 2002, Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project, Eur Urol, 42, 323, 10.1016/S0302-2838(02)00354-8 Culp, 2020, Recent global patterns in prostate cancer incidence and mortality rates, Eur Urol, 77, 38, 10.1016/j.eururo.2019.08.005 Adolfsson, 1998, Urinary and bowel symptoms in men with and without prostate cancer: results from an observational study in the Stockholm area, Eur Urol, 33, 11, 10.1159/000019528 Òrsted, 2011, Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men, Eur Urol, 60, 691, 10.1016/j.eururo.2011.06.016 Alcaraz, 2009, Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review, Eur Urol, 55, 864, 10.1016/j.eururo.2008.11.011 Schenk, 2011, Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial, Am J Epidemiol, 173, 1419, 10.1093/aje/kwq493 Frånlund, 2012, The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial, BJU Int, 110, 638, 10.1111/j.1464-410X.2012.10962.x Simon, 2016, Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE Trial, Eur Urol, 69, 885, 10.1016/j.eururo.2015.12.002 Gravas, 2020, EAU guidelines on management of non-neurogenic male LUTS, Arnhem, The Netherlands: EAU Young, 2000, Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence, BJU Int, 85, 1037, 10.1046/j.1464-410x.2000.00659.x Schulman, 2003, Awareness of prostate cancer among the general public: findings of an independent international survey, Eur Urol, 44, 294, 10.1016/S0302-2838(03)00200-8 Ward, 1999, GPs estimates of men’s risk of prostate cancer and screening expectations, Aust N Z J Public Health, 23, 219, 10.1111/j.1467-842X.1999.tb01243.x Nordström, 2013, Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003–2011, Eur Urol, 63, 419, 10.1016/j.eururo.2012.10.001 Grönberg, 2015, Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study, Lancet Oncol, 16, 1667, 10.1016/S1470-2045(15)00361-7 Ström, 2018, The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential, Eur Urol, 74, 204, 10.1016/j.eururo.2017.12.028